S&P Futures
4,381.50 -93.25 (-2.08%) Dow Futures
33,992.00 -261.00 (-0.76%) Nasdaq Futures
14,308.00 -193.00 (-1.33%) Russell 2000 Futures
2,008.40 -23.30 (-1.15%) Crude Oil
undefined (0) Gold
1,841.10 -0.60 (-0.03%)
Enveric Biosciences, Inc. (ENVB)
After hours:
Chart Events
Performance Outlook
| Previous Close | 0.6316 |
| Open | 0.6000 |
| Bid | 0.6201 x 1100 |
| Ask | 0.6300 x 1000 |
| Day's Range | 0.5500 - 0.6200 |
| 52 Week Range | 0.5500 - 7.0000 |
| Volume | |
| Avg. Volume | 843,327 |
| Market Cap | 19.458M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.6740 |
| Earnings Date | Nov 23, 2021 - Nov 24, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Apr 23, 2008 |
| 1y Target Est | 6.50 |
- PR Newswire
Enveric Biosciences CEO, Dr. Joseph Tucker, Provides 2021 Year in Review and 2022 Outlook in Letter to Shareholders
Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-centric biotechnology company, today released a letter to shareholders from Dr. Joseph Tucker, Chief Executive Officer of Enveric Biosciences.
- PR Newswire
Enveric Biosciences to Participate in the H.C. Wainwright BioConnect Conference on January 10-13, 2022
Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-centric biotechnology company developing next-generation mental health and oncology treatments by leveraging psychedelic-derived molecules for the mind and synthetic cannabinoids for the body, today announced that Dr. Joseph Tucker, Chief Executive Officer of Enveric Biosciences, will participate in the H.C. Wainwright BioConnect Conference to be hosted virtually on January 10-13, 2022.
- PR Newswire
Enveric Biosciences Appoints Dr. Bob Dagher as Chief Medical Officer
Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-centric biotechnology company developing next-generation mental health and oncology treatments by leveraging psychedelic-derived molecules for the mind and synthetic cannabinoids for the body, today announced the appointment of Bob Dagher, MD, as Chief Medical Officer, effective immediately.
